Results 11 to 20 of about 10,600 (216)
Herpes zoster following vaccination with ChAdOx1 nCoV-19 Coronavirus vaccine (recombinant)
Indian Journal of Public Health, 2022 Ever since the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, science has unraveled much knowledge on SARS-CoV-2 which has led to extraordinary and unprecedented progress in developing COVID-19 vaccines.
Anupa Mary Job +3 more
doaj +3 more sources
Herpes Zoster Following Recombinant Zoster Vaccine With or Without Concomitant Vaccination [PDF]
Open Forum Infectious Diseases, 2022 Abstract Background The 2-dose recombinant zoster vaccine (RZV) series is recommended for prevention of herpes zoster (HZ) in adults aged ≥50 years, but data are limited on the impact of concomitant administration with other vaccines on subsequent HZ risk.
Katia J Bruxvoort +8 more
openaire +2 more sources
Preventing Varicella-Zoster: Advances With the Recombinant Zoster Vaccine [PDF]
Open Forum Infectious Diseases, 2020 AbstractPrevention strategies against varicella zoster infection include chemoprophylaxis with acyclovir and live attenuated zoster vaccine. However, resistance to acyclovir has been problematic, and safety concerns have limited the use of the live attenuated vaccine in immunosuppressed patients.
Ilyas, Sahrish +1 more
openaire +2 more sources
Zoster Vaccine Recombinant, Adjuvanted [PDF]
Hospital Pharmacy, 2018 Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing
Kalvin, Stoker +2 more
openaire +2 more sources
Rhabdomyolysis after recombinant zoster vaccination: a rare adverse reaction [PDF]
Journal of Community Hospital Internal Medicine Perspectives, 2021 We present a case report describing a potential rare adverse reaction of the recombinant zoster vaccination. This patient is a 60-year-old female who was admitted for severe rhabdomyolysis after receiving the vaccine. The patient's symptoms and CPK improved with aggressive hydration over several days.
Nishan Rajaratnam +4 more
openaire +3 more sources
Estimated Public Health Impact of the Recombinant Zoster Vaccine [PDF]
Mayo Clinic Proceedings: Innovations, Quality & Outcomes, 2021 To investigate the potential public health impact of adult herpes zoster (HZ) vaccination with the adjuvanted recombinant zoster vaccine (RZV) in the United States in the first 15 years after launch.We used a publicly available model accounting for national population characteristics and HZ epidemiological data, vaccine characteristics from clinical ...
Brandon J. Patterson +7 more
openaire +3 more sources
Recombinant zoster vaccine and the risk of dementia. [PDF]
VaccineHerpes zoster is a potential risk factor for dementia. The effectiveness of the recombinant zoster vaccine for preventing dementia is uncertain.This retrospective cohort study used de-identified claims data from the Optum Labs Data Warehouse database from January 1, 2017, to December 31, 2022, to determine whether the recombinant zoster vaccine is ...
Tang E, Ray I, Arnold BF, Acharya NR.
europepmc +4 more sources
Recombinant zoster vaccine is associated with lower risk of dementia in adults aged ≥65 years [PDF]
Alzheimers DementAbstract Background Vaccines to prevent herpes zoster, historically zoster vaccine live (ZVL), have been associated with reduced dementia risk. We evaluated the association between recombinant zoster vaccine (RZV) and reduction in all‐cause dementia in adults aged ≥65 years at Kaiser Permanente Southern California.
Rayens E +12 more
europepmc +2 more sources
Adjuvanted Recombinant Glycoprotein E Herpes Zoster Vaccine [PDF]
Clinical Infectious Diseases, 2019 Abstract The adjuvanted recombinant glycoprotein E herpes zoster (HZ) vaccine is superior to the live attenuated HZ vaccine, with an efficacy >90% against HZ in healthy immunocompetent adults aged ≥50 years after vaccination. In pivotal studies, the efficacy of the new vaccine varied very little with the age of the vaccinee and ...
Myron J, Levin, Adriana, Weinberg
openaire +2 more sources
Viruses, 2023 Herpes zoster (HZ) is a disease caused by the reactivation of latent varicella-zoster virus (VZV). The subunit vaccine, Shingrix®, and live attenuated vaccine, Zostavax®, could be used as an HZ vaccine that prevents HZ from being developed due to the ...
Yanpeng Zheng +8 more
doaj +1 more source